550 results match your criteria Aids Reviews[Journal]

Humanized mouse models for preclinical evaluation of HIV cure strategies.

AIDS Rev 2022 May 27. Epub 2022 May 27.

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Although the world is currently focused on the COVID-19 pandemic, HIV/AIDS remains a significant threat to public health. To date, the HIV/AIDS pandemic has claimed the lives of over 36 million people, while nearly 38 million people are currently living with the virus. Despite the undeniable success of antiretroviral therapy (ART) in controlling HIV, the medications are not curative. Read More

View Article and Full-Text PDF

News from CROI 2022 - caveats using antiretrovirals as HIV prophylaxis.

AIDS Rev 2022 May 11. Epub 2022 May 11.

UNIR Health Sciences School & Medical, Center, Madrid, Spain.

View Article and Full-Text PDF

A cure for HIV on the horizon.

AIDS Rev 2022 May 11. Epub 2022 May 11.

UNIR Health Sciences School & Medical Center, Madrid, Spain.

View Article and Full-Text PDF

Research progress on HIV-1 immune escape mechanisms.

AIDS Rev 2022 May 3. Epub 2022 May 3.

Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Although highly active antiretroviral therapy has transformed HIV-1 infection into a manageable chronic disease, the development of an effective vaccine is still an important and challengeable research field of HIV-1 treatment. The challenge arises from an enormous diversity of HIV-1 strains and their rapid evolution ahead of effective immune responses. HIV-1 evasion from host immunity contributes to viral spread and pathogenesis, thus understanding the mechanisms of HIV-1 immune evasion is important. Read More

View Article and Full-Text PDF

Unexplained hepatitis in children after lifting COVID-19 pandemic restrictions.

Pablo Barreiro

AIDS Rev 2022 Apr 27. Epub 2022 Apr 27.

Laboratorio Regional de Salud Pública, Comunidad de Madrid, Madrid, Spain.

View Article and Full-Text PDF

Malignancies in people living with HIV.

AIDS Rev 2022 Mar 23. Epub 2022 Mar 23.

Department of Infectious Diseases, The 1st Affiliated Hospital of Nanchang University, Nanchang, China.

Almost 40 years have passed since the first case of what is known as AIDS was documented. In these 40 years, AIDS has always been a research challenge and hot spot. Researchers and scientists have made tremendous progress in basic and clinical research on HIV. Read More

View Article and Full-Text PDF

A greater virulent HIV-1 subtype B variant has circulated in The Netherlands since the 1990's.

AIDS Rev 2022 Mar 1;24(1):50. Epub 2022 Mar 1.

UNIR Health Sciences School and Medical Center, Madrid, Spain.

View Article and Full-Text PDF

Relationship between cytokine storm and SARS-CoV-2 infection's worsening.

AIDS Rev 2022 Feb 8. Epub 2022 Feb 8.

Physiology, Physiopathology and Biochemistry of Nutrition Laboratory, Tlemcen, Algeria.

View Article and Full-Text PDF
February 2022

Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.

AIDS Rev 2022 03 1;24(1):41-49. Epub 2022 Mar 1.

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska, Medical Center, NE, USA.

Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-threatening viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 disease manifestations and complications. However, waning immunity and emergence of vaccine escape mutants remains a growing threat. Read More

View Article and Full-Text PDF

Risk factors associated with pulmonary arterial hypertension among HIV-infected adults: A meta-analysis and systematic review.

AIDS Rev 2022 Jan 13. Epub 2022 Jan 13.

Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Pulmonary arterial hypertension (PAH) occurs more frequently in patients with HIV infection than in general population. The predictive value of HIV-related factors and traditional cardiovascular factors with PAH is inconsistent across studies. The objective is to determine the roles of HIV-related risk factors and traditional cardiovascular risk factors in the development of PAH in adults with HIV. Read More

View Article and Full-Text PDF
January 2022

Determinants of natural HIV-1 control.

AIDS Rev 2021 01 12. Epub 2021 Jan 12.

HIV Pathogenesis Programme, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.

HIV-1 infection usually progresses to AIDS within 10 years in antiretroviral therapy untreated individuals, but there is a group of infected individuals, known as controllers, who maintain low plasma HIV-1 RNA levels and normal CD4+ T-cell counts for many years. Evidence suggests that the mechanisms of viral control in these individuals are heterogeneous. In this review, we highlight the viral and host factors, particularly host immunological and immunogenetic factors that are associated with controller status. Read More

View Article and Full-Text PDF
January 2021

The opioid epidemic during the COVID-19 pandemic: Impact on HIV and HCV control.

AIDS Rev 2021 12 29;23(4):227. Epub 2021 Dec 29.

UNIR Health Sciences School and Medical Center, Madrid, Spain.

View Article and Full-Text PDF
December 2021

Another patient has cured HIV infection.

AIDS Rev 2021 12 29;23(4):226-227. Epub 2021 Dec 29.

UNIR Health Sciences School and Medical Center, Madrid, Spain.

View Article and Full-Text PDF
December 2021

Central nervous system disorders in HIV-infected individuals using distinct antiretroviral drugs.

Álvaro Mena

AIDS Rev 2021 ;23(4):214-225

Infectious Diseases Unit, Internal Medicine Service, Grupo de Virología Clínica Biobanco A Coruña, Área Sanitaria da Coruña e Cee-INIBIC, A Coruña, Spain.

Neuropsychiatric disorders and central nervous system-related symptoms are very common in people with HIV and can have a very negative impact on their quality of life and worsen the prognosis of the disease. These disorders are multifactorial in origin, but may be triggered or worsened by the use of certain antiretroviral treatments. This paper reviews the epidemiology of neuropsychiatric disorders and symptoms in people with HIV, the recommendations and tools available for their early assessment, as well as the neurotoxicity of the main families of antiretroviral (ARV) drugs. Read More

View Article and Full-Text PDF
January 2022

Study of quality of life and depression in people living with HIV/AIDS in India.

AIDS Rev 2021 ;23(4):186-195

Kasturba Medical College, Manipal, India.

The aim of this study was to assess the quality of life (QOL) and the severity of depression in people living with HIV/AIDS (PLWHA) and investigate its correlates. This was a cross-sectional study on 700 PLWHA in India. World Health Organization QOL HIV (WHOQOL HIV-BREF) and Patient Health Questionnaire-9 (PHQ-9) were used to assess QOL and depression in PLWHA, respectively. Read More

View Article and Full-Text PDF
January 2022

Nutritional assessment in the HIV-infected older population receiving antiretroviral therapy.

AIDS Rev 2021 Dec 22. Epub 2021 Dec 22.

Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.

Malnutrition is a pronounced public health issue which often seems underestimated in the older people living with HIV (PLWH) virus infection. PLWH are highly vulnerable to nutritional problems resulting from agingrelated deterioration, disease itself, and adverse effects of antiretroviral therapy (ART). The comprehensive nutritional assessments are necessary to perform routinely in this population to monitor and provide appropriate interventions to reduce comorbid conditions. Read More

View Article and Full-Text PDF
December 2021

Mobile applications in HIV self-management: A systematic review of scientific literature.

AIDS Rev 2022 03 1;24(1):24-31. Epub 2022 Mar 1.

Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran.

Self-management through mHealth by mobile apps creates new opportunities for people living with HIV (PLHIV) for integrated and accurate management. Our study focused on current evidence on HIV selfmanagement mobile applications to identify and assess their objective, infrastructure, and target populations. A systematic review was conducted on studies that use apps to improve self-management among HIV-positive patients, using PubMed, Scopus, Embase, Science direct, UpToDate, and Web of Science databases. Read More

View Article and Full-Text PDF

New insights into the genetics of same-sex behavior.

AIDS Rev 2021 10 4;23(3):164-166. Epub 2021 Oct 4.

Pellegrino's Group for Medical Ethics; Madrid, Spain.

View Article and Full-Text PDF
October 2021

A systematic review evaluating HIV prevalence among conflict-affected populations, 2005-2020.

AIDS Rev 2021 06 2;23(3):143-152. Epub 2021 Jun 2.

Center for Humanitarian Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Historically, there has been concern that conflict may exacerbate the HIV epidemic. We conducted a systematic review to examine HIV prevalence in conflict-affected populations compared to district-level or countrywide HIV prevalence. Following PRISMA guidelines, studies presenting original HIV prevalence data published between 2005 and 2020 were drawn from PubMed, Scopus, and Embase. Read More

View Article and Full-Text PDF

Dolutegravir in Mexico for special populations: A cost analysis perspective.

AIDS Rev 2021 07 1;23(3):126-132. Epub 2021 Jul 1.

ViiV Healthcare, Uruguay.

Integrase strand-transfer inhibitors (INSTI) are the latest class of antiretrovirals registered in Mexico. They include raltegravir (RAL), elvitegravir/cobicistat (EVG/c), dolutegravir (DTG) and bictegravir (BIC). Along with international guidelines, Mexico adopted the use of INSTI about two years ago as initial antiretroviral therapy (ART). Read More

View Article and Full-Text PDF

The Prevalence of HIV-infected Patients with Virological Suppression but a CD4 T-cell Count of ≤ 200 Cells/mm after Highly Active Antiretroviral Therapy Initiation: A Meta-analysis.

AIDS Rev 2022 03 1;24(1):16-23. Epub 2022 Mar 1.

The First Clinical Medical School, Henan University of Traditional Chinese Medicine. Zhengzhou, China.

Highly active antiretroviral therapy (HAART) strongly inhibits HIV replication. However, many patients show suboptimal immune recovery (SIR), as defined by virological suppression (i.e. Read More

View Article and Full-Text PDF

COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter.

AIDS Rev 2021 Jun 7;23(2):115-116. Epub 2021 Jun 7.

Department of Infectious Diseases, University Hospital Crosshouse, Kilmarnock, Scotland, UK University of Glasgow School of Medicine, Glasgow, Scotland, UK.

The arrival of coronavirus disease (COVID-19) in Europe exploded initially in North Italy and soon thereafter at several other major European cities, including Madrid. Indeed, Madrid was the epicenter of SARSCoV-2 infection in Spain, with a dramatic surge of cases since mid-March 2020. Read More

View Article and Full-Text PDF

Sarcopenia in Persons Living with HIV under Antiretroviral Therapy: Literature Review.

AIDS Rev 2022 03 1;24(1):1-15. Epub 2022 Mar 1.

Public Health School; School of Arts, Sciences and Humanities. University of São Paulo, São Paulo, Brazil.

The epidemiological profile of people living with HIV (PLWH) has expressively changed since the introduction of antiretroviral therapy (ART), from a high mortality rate to a profile similar to those living with chronic diseases. Despite the advances and effectiveness of ART, there are still various challenges to overcome, and we highlight the increased risk of sarcopenia in PLWH. This review study aims to (i) explore the pathophysiological background of sarcopenia in PLWH under the different existing ART and (ii) develop a mini-systematic review searching epidemiological studies investigating sarcopenia prevalence in PLWH. Read More

View Article and Full-Text PDF

Safety of Antiretroviral Therapy in the Treatment of HIV/AIDS in Children: Systematic Review and Meta-analysis.

AIDS Rev 2021 12 29;23(4):196-203. Epub 2021 Dec 29.

Pharmacy Department, Federal University of Paraná. Curitiba-PR, Brazil.

The safety of using different antiretroviral therapies (ART) in pediatric HIV/AIDS patients is not well-established. Therefore, this study aimed to assess the safety of ART in children. A systematic review of randomized clinical trials (RCTs) was conducted to assess the safety of ART used by pediatric patients living with HIV/AIDS. Read More

View Article and Full-Text PDF
December 2021

Differentials of SARS-CoV-2 Viral RNA Re-positivity in Discharged COVID-19 Patients.

AIDS Rev 2021 06 3;23(3):153-163. Epub 2021 Jun 3.

Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Cancer Research Institute, University of South China, Hunan, Hengyang, China.

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious RNA coronavirus responsible for the pandemic of the coronavirus disease 2019 (COVID-19). Recent advances in virology, epidemiology, diagnosis, and clinical management of COVID-19 have contributed to the control and prevention of this disease, but re-positivity of SARS-CoV-2 in recovered COVID-19 patients has brought a new challenge for this worldwide anti-viral battle. Reverse transcription polymerase chain reaction (RT-PCR) tests of the SARS-CoV-2 pathogen is widely used in clinical diagnosis, but a positive RT-PCR result may be multifactorial, including false positive, SARS-CoV-2 RNA fragment shedding, reinfection of SARS-CoV-2, or re-activation of COVID-19. Read More

View Article and Full-Text PDF

Efficacy and Safety of Triple versus Dolutegravir-based Dual Therapy in Patients with HIV-1 Infection: A Meta-analysis of Randomized Controlled Trials.

AIDS Rev 2021 06 3;23(3):133-142. Epub 2021 Jun 3.

Department of Evidence-based Medicine and Clinical Center; Department of Clinical Pharmacy; The First People's Hospital of Huaihua, University of South China, Huaihua, China.

A new strategy of simplification therapy shown the unique benefits in clinical treatment, by reducing pill burden and avoid drug exposure. To provide more evidence for the strategy, we compared the efficacy and safety of dolutegravir (DTG)-containing simplified dual combination antiretroviral therapy (cART) and traditional triple cART for people living with HIV/AIDS. The meta-analysis of randomized controlled trials compared DTG-containing dual therapy with triple cART. Read More

View Article and Full-Text PDF

"Moving Fourth": Introduction of a practical toolkit for shared decision-making to facilitate healthy living beyond HIV viral suppression.

AIDS Rev 2021 12 29;23(4):204-213. Epub 2021 Dec 29.

Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Modena, Italy.

An extension of the UNAIDS 90-90-90 target proposes >90% of people living with HIV (PLHIV) should have good health-related quality of life (HrQoL); however, limited guidance exists. The "Health Goals for Me" framework, an individualized approach to HIV care, provides a framework to assess HrQoL. We analyzed several patient-reported outcome measures (PROMs) to develop a practical toolkit to facilitate shared physician-patient decision-making. Read More

View Article and Full-Text PDF
December 2021

A Systematic Review and Meta-analysis to Estimate the Time from HIV Infection to Diagnosis for People with HIV.

AIDS Rev 2022 03 1;24(1):32-40. Epub 2022 Mar 1.

Department of Epidemiology, Robert Stempel College of Public Health and Social Work; Research Center in Minority Institutions (RCMI); Center for Research on U.S. Latino HIV/AIDS and Drug Abuse (CRUSADA). Florida International University, Miami, FL, USA.

Timely HIV diagnosis is critical to minimizing transmission events. We sought to estimate the meantime from HIV infection to diagnosis and its temporal trend among people with HIV. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a search of MEDLINE, Embase, and Google Scholar, supplemented by a hand search of bibliographies of articles, was conducted. Read More

View Article and Full-Text PDF

Is intermittent antiretroviral therapy a satisfactory strategy for the management of patients living with HIV?

AIDS Rev 2021 04 12;23(3):117-125. Epub 2021 Apr 12.

Department of Internal Medicine and Infectious Diseases, AIDS Reference Center, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels. Belgium.

Many innovations, such as long-acting agents, new delivery modalities (injectable and nanoparticles), and novel paradigms (immunotherapy or dual therapy), have been introduced to facilitate the administration of antiretroviral treatment (ART) to patients infected with HIV and improve their adherence and quality of life without altering the drugs' effectiveness. Studies have investigated the use of intermittent treatment, especially weekends-off ART in HIV-suppressed patients. In this review, we analyzed data concerning intermittent ART to help determine if this strategy is reasonable for the management of patients living with HIV. Read More

View Article and Full-Text PDF

Current situation and prospect of HIV-associated neurocognitive disorder research in China: Epidemiology, research, diagnosis, and treatment status.

AIDS Rev 2021 03 24;23(2):74-81. Epub 2021 Mar 24.

Department of Radiology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.

Standards of HIV/AIDS prevention and control in some areas of China are still poor. People live longer with the use of therapeutic drugs, which may lead to an increase in the number of HIV-associated neurocognitive disorders (HAND). However, only a few multicenter and large-scale studies investigating the prevalence and incidence of HAND have been undertaken in China. Read More

View Article and Full-Text PDF